A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?

[ad_1] In pharma, you can take a larger slice of the healthcare pie than your peers, but you are still constrained by the size of the pie. No matter how…

AstraZeneca to Buy Gracell Biotechnologies for $1.2 Billion

[ad_1] AstraZeneca has agreed to buy Gracell Biotechnologies for a transaction value of $1.2 billion, as part of the former’s efforts to grow its cell therapies business. The upfront cash…

AstraZeneca to Buy Icosavax for Up to $1.1 Bln

[ad_1] AstraZeneca said it would buy U.S.-based clinical-stage biopharmaceutical company Icosavax for up to $1.1 billion in a deal that expands its vaccines and immune therapies late-stage pipeline. The pharmaceutical…

The World Needs New Antibiotics, but the Business Model Is Broken

[ad_1] New drugs to defeat “superbug” bacteria aren’t reaching patients. [ad_2] Source link

Big Pharma’s Battle With the Biden Administration Could Have Legs

[ad_1] Wall Street should pay attention as the pharma industry mounts a widening legal campaign against the Inflation Reduction Act. [ad_2] Source link

AstraZeneca 1Q Profit Rose, But Decline in Covid-19 Drug Sales Hurt Revenue

[ad_1] AstraZeneca backed its 2023 guidance, after it posted a first-quarter profit of $1.8 billion, beating forecasts, but said revenue from Covid-19 medicines, including its vaccine, is expected to decline…

FTC Alerts Nearly 700 Companies About Potential Penalties for Misleading Claims

[ad_1] CMO Today Marketers will likely review their practices to avoid risking penalties that could stretch into the hundreds of millions of dollars [ad_2] Source link

Regeneron and Sanofi Look for Billions From COPD Drug

[ad_1] The companies said Dupixent showed positive results in a late-stage study of current or former smokers with the killer disease. [ad_2] Source link

International Stocks Lure Investors Seeking Bargains

[ad_1] Overseas companies and stock indexes have seen major rallies in recent months. [ad_2] Source link

Seagen’s Cancer Therapy Is Making It a Takeover Target

[ad_1] Health Novel cancer agents could shore up aging pharmaceutical portfolios for big drugmakers [ad_2] Source link